Tuesday, March 1, 2022

Financial News Conference on the Full Year 2021 Results

Bayer: Dynamic growth – progress in innovation

Group sales increase by 8.9 percent (Fx & portfolio adj.) to 44.081 billion euros
EBITDA before special items declines by 2.5 percent to 11.179 billion euros – inflation-related increase in costs and negative currency effects largely offset
Crop Science grows sales by double-digit percentage (Fx & portfolio adj.) and increases earnings
Pharmaceuticals posts higher sales – earnings decline slightly year on year due to extensive forward-looking investment
Consumer Health delivers excellent performance
Core earnings per share rise by 1.9 percent to 6.51 euros
Net income: 1 billion euros
Free cash flow (1.415 billion euros) and net financial debt (33.137 billion euros) much better than expected
Proposed dividend: 2.00 euros per share
Successful product launches and progress with platform technologies
Good progress with the implementation of long-term sustainability goals: direct and indirect CO2 emissions down by 11.5 percent
Outlook for 2022: Significant increase in sales, earnings and free cash flow